Article
Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers.
Transplantation and cellular therapy - 1 Aug 2026
Jiang Justin, Bhatta Subodh, Galloway Joshua, Lisath Solomon, Srisuwananukorn Andrew, Sharma Nidhi, Eisfeld Ann-Kathrin, Bumma Naresh, Devarakonda Srinivas Sankarnaga, Umyarova Elvira, Rosko Ashley Emily, Khan Abdullah Mohammad, Woyach Jennifer, Benson Don Michael, Borate Uma, Cottini Francesca
Abstract excerpt
Patients with lymphoid malignancies are at increased risk for second primary hematological malignancies (SPHM) due to reduced immune surveillance, genetic predispositions, and previous cancer therapies, including chemotherapy. SPHMs can substantially increase morbidity and mortality. In this study, we aim to characterize the clinical and genomic features, risk factors, and outcomes of patients who developed SPHMs...
Topics
Join the communities discussing this publication.